

# Eleftherios C Vamvakas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11881069/publications.pdf>

Version: 2024-02-01

78  
papers

4,089  
citations

147801

31  
h-index

114465

63  
g-index

81  
all docs

81  
docs citations

81  
times ranked

2946  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transfusion-Related Immunomodulation (TRIM): From Renal Allograft Survival to Postoperative Mortality in Cardiac Surgery. <i>Respiratory Medicine</i> , 2017, , 241-259.	0.1	2
2	Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. <i>Platelets</i> , 2015, 26, 154-163.	2.3	60
3	Allogeneic blood transfusion and cancer recurrence: 20 years later. <i>Transfusion</i> , 2014, 54, 2149-2153.	1.6	21
4	The abandoned controversy surrounding universal white blood cell reduction. <i>Blood Transfusion</i> , 2014, 12, 143-5.	0.4	4
5	Reasons for moving toward a patientâ€centric paradigm of clinical transfusion medicine practice. <i>Transfusion</i> , 2013, 53, 888-901.	1.6	35
6	Is best transfusion practice alone best clinical practice?. <i>Blood Transfusion</i> , 2013, 11, 172-4.	0.4	6
7	Risk-Reduction Strategies for Platelet Transfusion in the United States. <i>Scientific World Journal</i> , The, 2011, 11, 624-640.	2.1	11
8	Metaâ€analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogenâ€reduced platelets. <i>Transfusion</i> , 2011, 51, 1058-1071.	1.6	37
9	A patientâ€centric approach to preventing allergic reactions to platelet transfusions. <i>Transfusion</i> , 2011, 51, 1651-1653.	1.6	4
10	Relative Risk of Reducing the Lifetime Blood Donation Deferral for Men Who Have Had Sex With Men Versus Currently Tolerated Transfusion Risks. <i>Transfusion Medicine Reviews</i> , 2011, 25, 47-60.	2.0	24
11	Universal White Blood Cell Reduction in Europe: Has Transmission of Variant Creutzfeldt-Jakob Disease Been Prevented?. <i>Transfusion Medicine Reviews</i> , 2011, 25, 133-144.	2.0	11
12	Establishing Causation in Transfusion Medicine and Related Tribulations. <i>Transfusion Medicine Reviews</i> , 2011, 25, 81-88.	2.0	24
13	Meta-Analysis: A Statistical Method to Integrate Information Provided by Different Studies. , 2011, , 149-171.		0
14	BLOOD COMPONENTS: Metaâ€analysis of clinical studies of the purported deleterious effects of â€oldâ€ (versus â€freshâ€) red blood cells: are we at equipoise?. <i>Transfusion</i> , 2010, 50, 600-610.	1.6	86
15	Is Human Herpesvirus-8 Transmitted by Transfusion?. <i>Transfusion Medicine Reviews</i> , 2010, 24, 1-14.	2.0	23
16	Blood Still Kills: Six Strategies to Further Reduce Allogeneic Blood Transfusion-Related Mortality. <i>Transfusion Medicine Reviews</i> , 2010, 24, 77-124.	2.0	167
17	The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets. <i>Clinical Laboratory</i> , 2010, 56, 263-79.	0.5	6
18	Scientific Background on the Risk Engendered by Reducing the Lifetime Blood Donation Deferral Period for Men Who Have Sex With Men. <i>Transfusion Medicine Reviews</i> , 2009, 23, 85-102.	2.0	24

#	ARTICLE	IF	CITATIONS
19	Why are all men who have had sex with men even once since 1977 indefinitely deferred from donating blood?. <i>Transfusion</i> , 2009, 49, 1037-1042.	1.6	13
20	COMMENTARY: Relative safety of pooled whole bloodâ€‘derived versus singleâ€‘donor (apheresis) platelets in the United States: a systematic review of disparate risks. <i>Transfusion</i> , 2009, 49, 2743-2758.	1.6	68
21	Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. <i>Blood</i> , 2009, 113, 3406-3417.	1.4	524
22	Transfusion-related immunomodulation (TRIM): An update. <i>Blood Reviews</i> , 2007, 21, 327-348.	5.7	570
23	Current incidence and estimated residual risk of transfusionâ€‘transmitted infections in donations made to Canadian Blood Services. <i>Transfusion</i> , 2007, 47, 316-325.	1.6	131
24	Hepatitisÿ½B virus DNA?positive, hepatitisÿ½B surface antigen?negative blood donations intercepted by anti-hepatitisÿ½B core antigen testing: the Canadian Blood Services experience. <i>Transfusion</i> , 2007, 47, 1809-1815.	1.6	49
25	The Canadian Blood Donor Health Assessment Questionnaire: Lessons From History, Application of Cognitive Science Principles, and Recommendations for Change. <i>Transfusion Medicine Reviews</i> , 2007, 21, 205-222.	2.0	38
26	Pneumonia as a complication of blood product transfusion in the critically ill: Transfusion-related immunomodulation (TRIM). <i>Critical Care Medicine</i> , 2006, 34, S151-S159.	0.9	41
27	Predictive ability of sequential surveys in determining donor loss from increasingly stringent variant Creutzfeldt-Jakob disease deferral policies. <i>Transfusion</i> , 2006, 46, 461-468.	1.6	24
28	Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. <i>Transfusion</i> , 2006, 46, 492-494.	1.6	20
29	Face-to-face interviewing in predonation screening: lack of effect on detected human immunodeficiency virus and hepatitis C virus infections. <i>Transfusion</i> , 2006, 46, 1380-1387.	1.6	18
30	The Development of West Nile Virus Safety Policies by Canadian Blood Services: Guiding Principles and a Comparison Between Canada and the United States. <i>Transfusion Medicine Reviews</i> , 2006, 20, 97-109.	2.0	26
31	The Continuing Risk of Transfusion-Transmitted Infections. <i>New England Journal of Medicine</i> , 2006, 355, 1303-1305.	27.0	109
32	Deleterious Clinical Effects of Allogeneic Blood Transfusionâ€‘Related Immunomodulation. <i>Pathology Patterns Reviews</i> , 2006, 126, S71-S85.	0.4	2
33	Is White Blood Cell Reduction Equivalent to Antibody Screening in Preventing Transmission of Cytomegalovirus by Transfusion? A Review of the Literature and Meta-Analysis. <i>Transfusion Medicine Reviews</i> , 2005, 19, 181-199.	2.0	149
34	Evidence-based practice of transfusion medicine: Is it possible and what do the words mean?*1. <i>Transfusion Medicine Reviews</i> , 2004, 18, 267-278.	2.0	28
35	Pro and Con Discussion: Universal Leukoreduction. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2004, 6, 61-64.	0.2	0
36	Platelet transfusion and adverse outcomes. <i>Lancet</i> , The, 2004, 364, 1736-1738.	13.7	16

#	ARTICLE	IF	CITATIONS
37	Uses and sources of data on long-term survival after blood transfusion. <i>Transfusion Medicine Reviews</i> , 2003, 17, 194-208.	2.0	13
38	Ten-year survival of transfusion recipients identified by hepatitis C lookback. <i>Transfusion</i> , 2003, 43, 418-419.	1.6	13
39	WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. <i>Transfusion</i> , 2003, 43, 963-973.	1.6	69
40	Strength of the Evidence Generated From Reports of Clinical Research. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2003, 5, 303-309.	0.2	0
41	Applications of Meta-Analysis in Transfusion Medicine. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2003, 5, 311-318.	0.2	1
42	Can Policy Decisions in Transfusion Medicine Be Evidence-Based?. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2003, 5, 326-332.	0.2	2
43	Transfusion-Related Immunomodulation:.. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2002, 4, 12-16.	0.2	2
44	Possible mechanisms of allogeneic blood transfusion-associated postoperative infection. <i>Transfusion Medicine Reviews</i> , 2002, 16, 144-160.	2.0	148
45	Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: The effects of the type of transfused red blood cell product and surgical setting. <i>Transfusion Medicine Reviews</i> , 2002, 16, 304-314.	2.0	70
46	Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. <i>Transfusion</i> , 2002, 42, 107-113.	1.6	32
47	Four-year survival of transfusion recipients identified by hepatitis C lookback. <i>Transfusion</i> , 2002, 42, 691-697.	1.6	18
48	Assessment of the Quality of Clinical Research. <i>Vox Sanguinis</i> , 2002, 83, 397-401.	1.5	0
49	Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?. <i>Blood</i> , 2001, 97, 1180-1195.	1.4	388
50	Applications of Meta-Analysis in Pathology Practice. <i>Pathology Patterns Reviews</i> , 2001, 116, S47-S64.	0.4	3
51	Universal WBC reduction:the case for and against. <i>Transfusion</i> , 2001, 41, 691-712.	1.6	125
52	Allogeneic blood transfusion and postoperative duration of mechanical ventilation. <i>Transfusion</i> , 2001, 41, 885-892.	1.6	10
53	Long-term survival of transfusion recipients in Sweden, 1993. <i>Transfusion</i> , 2001, 41, 1173-1174.	1.6	5
54	RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. <i>Transfusion</i> , 2001, 41, 1413-1420.	1.6	74

#	ARTICLE	IF	CITATIONS
55	Evaluation of clinical studies of the efficacy of therapeutic apheresis. , 2000, 15, 6-17.		5
56	The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion, 2000, 40, 384-386.	1.6	6
57	Universal WBC reduction. Transfusion, 2000, 40, 751-752.	1.6	48
58	Multicenter randomized controlled trials in transfusion medicine. Transfusion Medicine Reviews, 2000, 14, 137-150.	2.0	14
59	Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. Transfusion Medicine Reviews, 2000, 14, 23-33.	2.0	38
60	Leukocyte reduction of blood components: Public policy and new technology. Transfusion Medicine Reviews, 2000, 14, 34-52.	2.0	123
61	Autologous transfusion and other approaches to reduce allogeneic blood exposure. Best Practice and Research in Clinical Haematology, 2000, 13, 533-547.	1.7	20
62	Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfusion Medicine Reviews, 1998, 12, 258-270.	2.0	68
63	Determinants of the efficacy of prophylactic granulocyte transfusions: A meta-analysis. Journal of Clinical Apheresis, 1997, 12, 74-81.	1.3	75
64	Rationale, objectives, and interpretation of randomized controlled trials. Journal of Clinical Apheresis, 1997, 12, 130-139.	1.3	6
65	Determinants of the efficacy of prophylactic granulocyte transfusions: A meta-analysis. Journal of Clinical Apheresis, 1997, 12, 74-81.	1.3	5
66	Applications of Therapeutic Apheresis in Patients with Malignant Disease. Oncologist, 1997, 2, 94-103.	3.7	6
67	Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. Journal of Clinical Apheresis, 1996, 11, 1-9.	1.3	90
68	Epidemiology of red blood cell utilization. Transfusion Medicine Reviews, 1996, 10, 44-61.	2.0	41
69	The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion, 1995, 35, 26-32.	1.6	73
70	Incidence of Delayed Hemolytic Transfusion Reactions. Vox Sanguinis, 1995, 69, 86-86.	1.5	2
71	Confounding and the Effect of Allogeneic Transfusion on Survival. Vox Sanguinis, 1995, 69, 142-143.	1.5	8
72	Effect of Autologous Transfusion on Length of Survival. Vox Sanguinis, 1995, 69, 147-148.	1.5	4

#	ARTICLE	IF	CITATIONS
73	Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. <i>Journal of Clinical Apheresis</i> , 1995, 10, 163-170.	1.3	36
74	Mortality After Blood Transfusion. <i>Transfusion Medicine Reviews</i> , 1994, 8, 267-280.	2.0	17
75	Endocervical gland involvement by cervical intraepithelial neoplasia grade III. predictive value for residual and/or recurrent disease. <i>Cancer</i> , 1991, 68, 1932-1936.	4.1	52
76	Herpes viruses. , 0, , 35-58.		0
77	Immunomodulatory and Proinflammatory Effects of Allogeneic Blood Transfusion. , 0, , 699-717.		2
78	Transfusion-Related Immunomodulation. , 0, , 98-106.		1